# Gary G Chiang

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 35 papers | 5,052 citations | 218381 26 h-index | 360668 35 g-index |
| 36 all docs | 36 docs citations | 36 times ranked | 9003 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Regulation of Hypoxia-Inducible Factor 1Î± Expression and Function by the Mammalian Target of Rapamycin. Molecular and Cellular Biology, 2002, 22, 7004-7014. | 1.1 | 1,106 |
| 2 | Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature, 2017, 550, 128-132. | 13.7 | 498 |
| 3 | Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 IsMediated by p70S6 Kinase. Journal of Biological Chemistry, 2005, 280, 25485-25490. | 1.6 | 478 |
| 4 | Targeting the mTOR signaling network in cancer. Trends in Molecular Medicine, 2007, 13, 433-442. | 3.5 | 306 |
| 5 | Comparative Metabolic Flux Profiling of Melanoma Cell Lines. Journal of Biological Chemistry, 2011, 286, 42626-42634. | 1.6 | 274 |
| 6 | Genotoxic Stress Targets Human Chk1 for Degradation by the Ubiquitin-Proteasome Pathway. Molecular Cell, 2005, 19, 607-618. | 4.5 | 259 |
| 7 | The EED proteinâ€“protein interaction inhibitor A-395 inactivates the PRC2 complex. Nature Chemical Biology, 2017, 13, 389-395. | 3.9 | 186 |
| 8 | Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a. ACS Medicinal Chemistry Letters, 2014, 5, 205-209. | 1.3 | 152 |
| 9 | Mammalian Target of Rapamycin Activator RHEB Is Frequently Overexpressed in Human Carcinomas and Is Critical and Sufficient for Skin Epithelial Carcinogenesis. Cancer Research, 2010, 70, 3287-3298. | 0.4 | 151 |
| 10 | Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorganic and Medicinal Chemistry, 2004, 12, 4749-4759. | 1.4 | 138 |
| 11 | Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Research, 2003, 63, 8451-60. | 0.4 | 137 |
| 12 | The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Molecular Cancer Therapeutics, 2007, 6, 2505-2514. | 1.9 | 131 |
| 13 | Specific Dephosphorylation of the Lck Tyrosine Protein Kinase at Tyr-394 by the SHP-1 Protein-tyrosine Phosphatase. Journal of Biological Chemistry, 2001, 276, 23173-23178. | 1.6 | 130 |
| 14 | REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4Aâ€“DDB1 ubiquitin ligase. EMBO Reports, 2009, 10, 866-872. | 2.0 | 126 |
| 15 | Structure-based Design of Pyridoneâ€“Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition. Journal of Medicinal Chemistry, 2018, 61, 3516-3540. | 2.9 | 118 |
| 16 | The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nature Chemical Biology, 2017, 13, 317-324. | 3.9 | 98 |
| 17 | Control of mTORC1 signaling by the Opitz syndrome protein MID1. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8680-8685. | 3.3 | 82 |
| 18 | Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Organic and Biomolecular Chemistry, 2004, 2, 1911. | 1.5 | 81 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. Journal of Medicinal Chemistry, 2020, 63, 5879-5955. | 2.9 | 78 |
| 20 | The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia. PLoS ONE, 2015, 10, e0131716. | 1.1 | 65 |
| 21 | The Role of Dbf4/Drf1-Dependent Kinase Cdc7 in DNA-Damage Checkpoint Control. Molecular Cell, 2008, 32, 862-869. | 4.5 | 60 |
| 22 | Tyrosine Phosphorylation of RNA Polymerase II Carboxyl-terminal Domain by the Abl-related Gene Product. Journal of Biological Chemistry, 1997, 272, 18905-18909. | 1.6 | 59 |
| 23 | Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Medicinal Chemistry Letters, 2015, 6, 695-700. | 1.3 | 58 |
| 24 | The FRB Domain of mTOR:Â NMR Solution Structure and Inhibitor Designâ€,â€¡. Biochemistry, 2006, 45, 10294-10302. | 1.2 | 47 |
| 25 | Phosphorylation of a Src Kinase at the Autophosphorylation Site in the Absence of Src Kinase Activity. Journal of Biological Chemistry, 2000, 275, 6055-6058. | 1.6 | 35 |
| 26 | Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. Molecular Cancer Therapeutics, 2021, 20, 26-36. | 1.9 | 35 |
| 27 | Design, Synthesis, and Structureâ^'Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway. Journal of Medicinal Chemistry, 2010, 53, 8368-8375. | 2.9 | 27 |
| 28 | SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1576-1583. | 1.0 | 26 |
| 29 | eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2015, 126, 1554-1554. | 0.6 | 25 |
| 30 | Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice. Cancer Research, 2010, 70, 8937-8947. | 0.4 | 17 |
| 31 | Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors. Frontiers in Oncology, 2021, 11, 766298. | 1.3 | 17 |
| 32 | Divergent S Phase Checkpoint Activation Arising from Prereplicative Complex Deficiency Controls Cell Survival. Molecular Biology of the Cell, 2009, 20, 3953-3964. | 0.9 | 16 |
| 33 | Effective inhibition of melanoma by BIâ€69A11 is mediated by dual targeting of the AKT and NFâ€ºB pathways. Pigment Cell and Melanoma Research, 2011, 24, 703-713. | 1.5 | 13 |
| 34 | Determination of the Catalytic Activities of mTOR and Other Members of the Phosphoinositide-3-Kinase-Related Kinase Family. , 2004, 281, 125-142. | | 11 |
| 35 | mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation. JCI Insight, 2021, 6, . | 2.3 | 9 |